# Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.

> PubMed lists PMID 31365765 in Diabetic medicine : a journal of the British Diabetic Association as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-11-26 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31365765-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31365765-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-31365765-lixisenatide-v1.json
- Content SHA-256: `8afab0d60556221eba2cc078dc24b6fd5e1513cab0e60ec9bba0d9fec5824c17`

## Claims and source pins

### Headline

Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials. ([`pubmed-observation-pmid-31365765-2026-01-27-e6483945acba`](#source-pubmed-observation-pmid-31365765-2026-01-27-e6483945acba))

### Summary

PubMed lists PMID 31365765 in Diabetic medicine : a journal of the British Diabetic Association as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-11-26 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31365765-2026-01-27-e6483945acba`](#source-pubmed-observation-pmid-31365765-2026-01-27-e6483945acba))

### Paragraph 1

PubMed lists PMID 31365765 in Diabetic medicine : a journal of the British Diabetic Association as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-11-26 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31365765-2026-01-27-e6483945acba`](#source-pubmed-observation-pmid-31365765-2026-01-27-e6483945acba))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31365765-2026-01-27-e6483945acba`](#source-pubmed-observation-pmid-31365765-2026-01-27-e6483945acba))

## Sources

<a id="source-pubmed-observation-pmid-31365765-2026-01-27-e6483945acba"></a>
- **Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials. · retained source version 1:2026-01-27:current:e6483945acbafb19aa5e8c24d72ca0995c20517316e4b93de46074aea7dc722a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31365765/) (`pubmed-observation-pmid-31365765-2026-01-27-e6483945acba`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-31365765-lixisenatide-v1.json SHA-256: 8afab0d60556221eba2cc078dc24b6fd5e1513cab0e60ec9bba0d9fec5824c17.